BUSINESS Dow ends up 1.9% in rebound on latest Trump stimulus comments


Dow ends up 1.9% in rebound on latest Trump stimulus comments

China Daily

09:32, October 08, 2020

FILE PHOTO: A street sign is seen in front of the New York Stock Exchange on Wall Street in New York, February 10, 2009. (Photo:Agencies)

NEW YORK - Wall Street stocks jumped Wednesday following more favorable comments from US President Donald Trump on fiscal stimulus spending amid positive sentiment on coronavirus therapeutics.

The Dow Jones Industrial Average gained 1.9 percent to finish the session at 28,303.46.

The broad-based S&P 500 advanced 1.7 percent to 3,419.44, while the tech-rich Nasdaq Composite Index surged 1.9 percent to 11,364.60.

After Trump's announcement Tuesday afternoon abruptly ending talks with congressional Democrats on additional stimulus until after the election, the president and his administration moved quickly to walk back the much-criticized statement.

On Tuesday night, Trump called for Congress to "immediately" pass stand-alone legislation to extend aid for airline workers and small businesses. He also said he would back another round of $1,200 stimulus payments for workers.

White House economic advisor Larry Kudlow told CNBC Wednesday that Trump backed targeted measures, adding, "I don't think the recovery depends on the massive assistance package."

Peter Hanks, a strategist at DailyFX, attributed the rally largely to the shift in tone from the White House, while expressing skepticism.

"Over the longer term, I think we'll need some clarity on this," Hanks said. "If we do come to see that stimulus isn't going to happen until the election, that could undermine some of these larger blue cap stocks, some of the airlines."

"I'm a little concerned for the rest of the week and maybe heading into next week," he added.

Besides the comments on stimulus, analysts said the market had become more optimistic about the presidential election given Democratic nominee Joe Biden's lead in the polls, which suggests that a drawn-out and contested outcome may be averted.

Another positive factor was pharma giant Eli Lilly's announcement that it applied for an emergency use authorization for a lab-produced antibody treatment against Covid-19, after early trial results showed it reduced viral load, symptoms and hospitalization rates.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue